Gina C. Wu
Overview
Gina Wu is a skilled transactional lawyer who counsels life sciences clients in structuring, drafting, and negotiating domestic and cross-border transactions for the research and development of drug, medical device, gene therapy, cell therapy, and diagnostic products.
Career & Education
- Interim Corporate Counsel, Citrix Systems, Inc
- Member of the Securities and Corporate Finance Group, Vancouver-based firm
- McGill University, B.Com.
- University of British Columbia, J.D.
- Massachusetts
- Washington State
- Member, Washington State Bar Association
- Member, Boston Bar Association
- Member, American Bar Association
- Vice-Chair, Securities Law section, Canadian Bar Association, British Columbia branch (2013–2014)
- Treasurer and Secretary, Securities Law section, Canadian Bar Association, British Columbia branch (2012–2013)
Gina's Insights
Client Alert | 4 min read | 12.09.25
In an effort to boost its clinical research industry, Germany has enacted the Medical Research Act or “MRA” (Medizinforschungsgesetz). The MRA introduces significant changes to various German healthcare laws and procedures.
Representative Matters
Licenses and Research Collaborations
- Represented not-for-profit client seeking to develop and commercialize treatments for rare disease in a license and research collaboration agreement opposite a prestigious research university.
- Represented an early-stage, venture-backed drug development client with complex gene coding product in connection with several in-licenses for patented manufacturing and delivery technologies.
- Drafted and negotiated sponsored research agreements with a leading pediatric hospital on behalf of venture-backed client with a gene editing product.
- Drafted and negotiated multiple evaluation and research and collaboration agreements with U.S. and ex-U.S. academic institutions to support development and validation of venture-backed client’s diagnostic device to detect molecular residual disease.
Manufacturing and Clinical Trials
- Drafted and negotiated various development and manufacturing agreements for GMP production of venture-backed client’s clinical-stage complex gene coding product.
- Drafted and negotiated development and GMP manufacturing agreement opposite a strategic partner for T-cell therapy drug products on behalf of clinical stage platform technology client.
- Advised a leading biopharmaceutical company formerly based in the United States as sponsor of various single-center and multi-center clinical trials, including a Phase 3 clinical trial involving approximately 520 subjects across sites located in the North America, Europe, and Asia.
- Oversaw contracting support for multiple clinical trials sponsored by a clinical-stage biopharmaceutical company developing transformative immunology-based therapies, including multinational Phase 3 trials involving sites in North America, South America, Europe, and Asia.
Gina's Insights
Client Alert | 4 min read | 12.09.25
In an effort to boost its clinical research industry, Germany has enacted the Medical Research Act or “MRA” (Medizinforschungsgesetz). The MRA introduces significant changes to various German healthcare laws and procedures.
Gina's Insights
Client Alert | 4 min read | 12.09.25
In an effort to boost its clinical research industry, Germany has enacted the Medical Research Act or “MRA” (Medizinforschungsgesetz). The MRA introduces significant changes to various German healthcare laws and procedures.
